Dr Mohamed Bouattour, Onco-hépatologie (thématique, carninome hépatocellulaire, cholangiocarcinome, cancers hépatiques rare)

Spécialité

Onco-hépatologie (thématique, carninome hépatocellulaire, cholangiocarcinome, cancers hépatiques rare)

Hôpital

Hôpital Beaujon (Clichy)

Derniers articles

Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. (1 sept. 2026)
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC). (6 août 2026)
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. (1 août 2026)
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib. (1 août 2026)
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study. (6 juil. 2026)